BridgeBio Pharma, Inc. (BBIO:NASDAQ) closed at $74.29 on November 6, 2026, up 0.03% on the day. The stock trades 20.5% below its 52-week high of $93.42 and 22.7% above its 52-week low of $60.55. Over the past year, it gained 20.2%. BridgeBio Pharma, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 6, 2025, BBIO closed higher on 122 days (48%). Its best day was July 9, 2026 (+15.12%) and its worst was February 5, 2026 (-15.24%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 3 times.
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Oncology and Gene therapy.
Find more stocks like BBIO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.